Please wait while we load the requested 10-K report or click the link below:
401 Congress, Suite 1650
|||GAAP results: net loss of $1.8 million, or $(0.10) per diluted share, for the quarter ended June 30, 2011 and net loss of $5.0 million, or $(0.28) per diluted share, for the year ended June 30, 2011|
|||EBITDA loss of $1.4 million for the quarter ended June 30, 2011 and $3.5 million for the year ended June 30, 2011|
|||GAAP cash flow of $6.9 million the year ended June 30, 2011 resulting in $15.0 million in cash and cash equivalents at June 30, 2011|
|||Astrotech Space Operations (ASO), supported the processing of six missions with successful launches in fiscal year ended June 30, 2011|
|||Astrotech works to reduce controllable costs, lowering SG&A $3.8 million versus fiscal year 2010, allowing for investment in the ASO core business and growth initiatives at Spacetech|
Astrogenetix continued maximizing flight opportunities in fiscal year 2011 in the process of developing products from microgravity discoveries with a focus on vaccines for Salmonella and Methicillin-resistant Staphylococcus aureus (MRSA). Astrogenetix completed its twelfth microgravity research mission on NASAs STS-134 in the fourth quarter of fiscal 2011. The mission was Space Shuttle Endeavours final mission.
The following information was filed by Astrotech Corp (ASTC) on Tuesday, September 20, 2011 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-K Annual Report statement of earnings and operation as management may choose to highlight particular information in the press release.
View differences made from one year to another to evaluate Astrotech Corp's financial trajectory
Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were
removed , and by Astrotech Corp.